Yesterday, representatives from Immunovaccine Inc. announced that the company has signed a collaborative research agreement with Vaxil BioTherapeutics. The research agreement aims to explore the efficacy of Vaxil’s cancer antigens in its Immunovaccine’s DepoVax™ vaccine enhancement platform.
Headquartered in Israel, Vaxil BioTherapeutics is a pioneer in T-cell synthetic vaccines development for therapeutic and prophylactic use. The company has identified a large number of vaccine candidates in the fields of cancer and infectious diseases using its proprietary technology VaxHit™. In other news, ImMucin™, the company’s lead product, has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients, due to commence in 2010.
“Vaxil has an innovative approach for identifying cancer antigens that get presented more efficiently by the MHC molecules. Vaxil’s long peptides are good candidates for formulation in our DepoVax™ platform making this an interesting research partnership” remarked Dr. Marc Mansour, vice president of R&D at Immunovaccine.
Dr. Lior Carmon, founder and CEO of Vaxil BioTherapeutics, added, “In preclinical studies, the DepoVax™ delivery platform has a demonstrated ability to enhance vaccines, generating a prolonged immune response. We believe that this could fit well with our products and we look forward to making strong advances together in developing the next generation of cancer therapeutics.”
For more information, please visit the company’s website at www.vaxilbio.com